DEXCOM INC — Form 8-K
Filed October 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 42/100
What the filing says
Dexcom reported Q3 2026 revenue of $1.344B (+11% YoY), with U.S. revenue growing 14% and international 5%. GAAP operating income reached $327.2M (24.3% margin, +420 bps YoY); non-GAAP operating income $339.5M (25.3% margin, +270 bps YoY). The company raised FY2026 revenue guidance to $5.20–$5.25B (~12–13% growth), increased non-GAAP operating margin guidance to ~24%, and announced a $1.0B share repurchase authorization. Cash position stands at $1.82B.
Why this rating
Solid execution with margin expansion and guidance raise; revenue growth in low double-digits is modest relative to company size (~$34B market cap). Event represents normal growth trajectory, not transformational.
See more from October 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.